Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Afatinib in Resected EGFR-mutant NSCLC
NCT01746251Phase 2Unknown
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2013
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of afatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Recurrence-Free Survival at 2 years. Status: unknown.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01746251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01746251.